Theravance Discloses Three Merger Lawsuits and Supplemental Proxy Details Ahead of Sept 18 Vote
TBPH sits 30% above its 52-week low of $13.08.
Summary
Theravance Biopharma disclosed three shareholder lawsuits and thirteen demand letters alleging proxy disclosure deficiencies related to its pending $17.00 per share acquisition by Zymeworks, and voluntarily supplemented the proxy with additional financial details.
Key Events · M&A and Partnerships · TBPH
-
Three Merger Lawsuits Filed
Three shareholder complaints (Richardson, Thompson, Maglione) filed in New York and California courts seek to enjoin the merger unless additional disclosures are made, plus rescission or damages if the merger closes.
-
Thirteen Demand Letters Received
Law firms representing purported shareholders sent thirteen demand letters alleging disclosure deficiencies in the proxy statement.
-
Supplemental Proxy Disclosures
Company voluntarily supplemented the proxy with new details including Evercore's $7 million fee upon merger consummation, Lazard's net debt of approximately $(385) million, and 54.9 million fully diluted shares.
-
Lazard Implied Equity Value Range
Lazard's analysis implied an equity value range of $15.25 to $16.25 per share, below the $17.00 per share merger consideration.
Analysis · TBPH · Life Sciences
With the shareholder vote on the $17.00 per share Zymeworks acquisition just eight days away, Theravance Biopharma has disclosed three shareholder lawsuits and thirteen demand letters challenging the adequacy of its proxy disclosures. The company denies the allegations but voluntarily supplemented the proxy with new details, including Evercore's $7 million fee, Lazard's net debt figure of approximately $(385) million, and an implied equity value range of $15.25 to $16.25 per share. These developments add uncertainty to the merger timeline and may influence how shareholders evaluate the deal.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 29.9% of the 1988 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TBPH was trading at $17.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $885.7M. The 52-week trading range was $13.08 to $21.03. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.